维多利祖马布用于儿科炎性肠病的肠外表现:VedoKids研究的结果
Giulia D'Arcangelo1,2, Dan Turner3, Oren Ledder3
1Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
儿科炎症性肠病 (IBD) 患者的肠外表现 (EIM) 经常通过vedolizumab治疗得到解决. 然而,近一半的这些儿童在治疗期间需要同时服用药物.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 免疫学 免疫学 免疫学
- 临床治疗学 临床治疗学
背景情况:
- 肠外表现 (EIMs) 影响了很大一部分炎症性肠病 (IBD) 患者.
- 在儿科IBD中描述EIM对于优化治疗策略至关重要.
研究的目的:
- 分析小儿IBD患者治疗vedolizumab的EIM的过程和结果.
- 评估EIMs对小孩vedolizumab治疗耐久性的影响.
主要方法:
- 对前性多中心VedoKids队列研究的子组分析.
- 纳入儿科患者 (0-18岁) 患有IBD,接受维多利祖马布治疗,随访54周.
- 从基线到后续行动中识别和跟踪EIM.
主要成果:
- 12.6%的儿科IBD患者在基线时有EIM,主要是关节.
- 89%的EIM在18个月内得到解决.
- 在72%的EIM病例中,同时使用药物;EIM存在没有影响vedolizumab的耐用性.
结论:
- 维多利祖马布治疗与儿科IBD中大多数EIM的消失有关.
- 同时使用药物在患有EIM的儿科IBD患者中很常见.
- 维多利祖马布在这个儿科队列中,无论EIM如何,都显示出持久的疗效.
更多相关视频
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
